{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:14:35Z","timestamp":1720224875182},"reference-count":3,"publisher":"Oxford University Press (OUP)","issue":"S1","license":[{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:p>In an update from the ongoing phase II ZUMA-5 trial, axicabtagene ciloleucel showed a high response rate and durable clinical benefit in patients with relapsed\/refractory indolent non-Hodgkin lymphoma, including follicular lymphoma and marginal zone lymphoma.<\/jats:p>","DOI":"10.1634\/theoncologist.2020-0559","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T08:01:36Z","timestamp":1593244896000},"page":"S6-S7","source":"Crossref","is-referenced-by-count":3,"title":["CAR T-Cell Therapy Shows Durable Responses in Indolent NHL"],"prefix":"10.1093","volume":"25","member":"286","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"key":"2021122511444745200_onco13427-bib-0001","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: An analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122511444745200_onco13427-bib-0002","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"2021122511444745200_onco13427-bib-0003","author":"Jacobson"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1634%2Ftheoncologist.2020-0559","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2020-0559","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2020-0559","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/S1\/S6\/41923069\/oncolo_25_s1_s6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/S1\/S6\/41923069\/oncolo_25_s1_s6.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T11:44:57Z","timestamp":1640432697000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/S1\/S6\/6443571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":3,"journal-issue":{"issue":"S1","published-online":{"date-parts":[[2020,6,26]]},"published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2020-0559","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7,1]]},"published":{"date-parts":[[2020,6,26]]}}}